PROMISE-meso trial results: Pembrolizumab vs chemotherapy for advanced pleural mesothelioma
PROMISE-meso trial results: Pembrolizumab vs chemotherapy for advanced pleural mesothelioma
KATHERINE trial updates for HER2-positive breast cancer
PARP inhibitors for metastatic breast cancer
TRITON2: Rucaparib for metastatic castration-resistant prostate cancer
Lutetium-177 PSMA scanning for prostate cancer
Highlights from ESMO 2019
SPICE: Analysis of enadenotucirev plus nivolumab in metastatic colorectal cancer patients during the dose escalation phase
Pembrolizumab plus platinum-based chemotherapy for metastatic NSCLC
Association between tTMB and clinical outcomes with pembrolizumab alone in PD-L1-positive advanced NSCLC in KEYNOTE-010 and -042
AMG 510: A novel molecule targeting KRAS G12C mutant solid tumours
MEDIOLA: Olaparib and durvalumab for germline BRCA-mutated metastatic breast cancer
Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer